Biocryst Pharmaceuticals
Presença
Biocryst Pharmaceuticals é uma das ...
Biocryst Pharmaceuticals é uma empresa listada sob o símbolo BCRX (US).
Executivos
Veja o organograma con seus 24 executivos principais
Biografias mais buscadas da Biocryst Pharmaceuticals
- Jon Stonehouse, President, Chief Executive Officer, Director
- Amy McKee, Director
- George Abercrombie, Director
Recentes movimentos de executivos em Biocryst Pharmaceuticals
- Kenneth Lee, Director, deixará a Companhia em 31 de dez. de 2023 (Notícia publicada em 4 de dezembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Biocryst Pharmaceuticals.
Biotecnologia
Biocryst Pharmaceuticals possui 2.277 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado em 18 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado em 16 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Biocryst Pharmaceuticals
- BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
- BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
- BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
- BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
- BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
- BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
- BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
- BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
- BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
- BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
- View more press releases Close
Redes sociais sobre Biocryst Pharmaceuticals
- Biocryst Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Biocryst Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Jon Stonehouse 
Ligue para a Biocryst Pharmaceuticals em +1 919...
